Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Auburn University Applied Research Institute to oversee $50m Army advanced manufacturing project
Auburn University, located in Auburn, Alabama, in the US, has received what is the single largest prime research contract ever awarded to the institution, a 50 million USD contract that is designed to help the U.S. Army Combat Capabilities Development Command Aviation & Missile Center boost its increasing modernisation efforts.
The project made possible by the funding is titled “Lightweight, Advanced Manufacturing of Metallic, Polymer and Composite Structures for Aviation and Missile Weapon Systems,” and will be facilitated through the Auburn University Applied Research Institute (AUARI) in Huntsville.
The project will also rely on research expertise from Auburn’s National Center for Additive Manufacturing Excellence (NCAME), and the Interdisciplinary Center for Advanced Manufacturing Systems (ICAMS).
9.3 million USD of the award has already been designated for NCAME, which will use the funds to continue its research into the materials, parts and process qualification necessary for furthering the implementation of additive manufacturing in Army operations.
CMCs are a subgroup of composite materials that consist of ceramic fibers embedded in a ceramic matrix. Because of their high temperature resistance and low density, researchers for decades have investigated using CMCs in aerospace applications. In recent years, some of these dreams reached fruition, for example, when the LEAP aircraft engine by GE Aviation, which contains CMC high-pressure turbine shrouds, entered commercial service in 2016.
The ability of CMCs to resist hostile environments is a recurring theme in many of the applications being explored. For example, in addition to gas turbine engines, researchers are investigating the use of CMCs as heat exchangers in next-generation energy technologies. Yet it is a different property of some CMCs that enables its less well-known application in radomes.
A radome is a structural, weatherproof enclosure that protects a radar antenna from the environment. For a radome to serve its purpose effectively, the material from which it is constructed must minimally attenuate the electromagnetic signal transmitted or received by the antenna—in other words, it must be transparent to radio waves
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
It’s a step in the right direction but the cancer still remains.
The company’s strong position within existing markets, such as the medical sector, will reportedly enable it to generate opportunities in new industrial applications, such as aeronautics.
In February of 2024, the company announced a multiple year supply agreement with a leading aerospace company.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Bal leaving can only be a good thing. He may string it along for awhile though. In the meantime, I'd suggest the following as his possible replacement: Bob Cotton, former CEO of Cotton and Western Mining; Rene Bracconier former CEO of Thermo Tech Technologies and the late Bob Lorsch, former CEO of MMRGlobal.
SO LONG SONNY, YOU WORTHLESS POS
$SINT
Biomedical printing is moving forward quickly it seems. Is the main difference that Prodways is a desktop? Size limitations?
https://www.sciencedirect.com/science/article/pii/S1010518224000738?via%3Dihub
SINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENT
SINTX and its subsidiary Technology Assessment and Transfer, Inc. will supply ceramic-filled printable slurries
SINTX now sells 3D printed components made from alumina, zirconia, and silica, and also supplies custom printable ceramic-filled resins to customers across multiple industries. In February of 2024, the company announced a multiple year supply agreement with a leading aerospace company.
SINTX will manufacture and supply key ceramic aircraft engine components which have been qualified through a rigorous evaluation process.
entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Army Research Laboratory (DEVCOM ARL). This partnership is expected to leverage the strengths of both organizations in the areas of ceramic additive manufacturing (ceramic 3D printing) and ceramic matrix composites (CMCs).
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz
Interesting... Perhaps a collaboration is in the works.
Could this simply be an issue of scale?
Prodways up to a certain size and 3DCERAM SINTO for larger prints?
The ceramics under development mostly comprise alumina and zirconia—high-density materials with good mechanical strength and corrosion resistance—and hydroxyapatite, a calcium phosphate found in teeth and bone. Lithoz has improved upon the latter bioceramic in its new bone graft substitute, LithaBone HA 480. Unveiled late last year, LithaBone increases the wall thickness (from <1.6mm to 10mm) and further reduces minimum wall thickness, broadening the range of its applications.
LithaBone HA 480 also has less overpolymerization but an improved depth of cure, which improves build parameters and induces a more stable manufacturing process. The material also has a longer shelf life and produces easier-to-clean parts.
SINTEX Technologies Inc.’s acquisition last summer of Technology Assessment and Transfer Inc. provided the Salt Lake City-based firm with the necessary processing equipment and novel composite filaments for manufacturing 3D printed implants from its silicone nitride material. SINTEX’s FleX-SN product family can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements. They are suitable as a dental implant material as well, thanks to their bacterial adhesion resistance.
3D Systems made a similar move last spring to diversify its AM capabilities from metal implants to PEEK products. Company executives said the purchase of Kumovis would benefit 3D Systems’s portfolio of craniomaxillofacial, bone plate, and spinal cage applications.
While AM has grown significantly in the orthopedic industry over the last two decades, experts say there are still some large-scale hurdles to overcome before the technology is used to its full advantage—cost, hardware, software, materials, and services, to name a few.
“We believe cost is still a challenge for 3D printing of components that are relatively large, driving low yields on a print run, and where markets are price sensitive, such as hip or knee replacement,” said Dave Anderson, co-founder and business development leader at Mach Medical, a Columbia City, Ind.-based orthopedic medical device contract manufacturer. “Adding to the cost challenge is the fact that, in many applications, 3D printing forces additional steps to the manufacturing process. For instance, 3D printed products will often require printing, heat treatments, cleaning, and inspection as incremental steps to the traditional process. This can add lead time, which will unfavorably impact inventory levels, and cost, which is harder to absorb with product price.”
Juan Chafino added regulatory validations and AM’s part-dependent nature to the list of hurdles the technology still faces. But he’s hopeful for the future, as he believes the technique is still in its infancy.
“As the technology matures, the process and process flow will become more industrial. As the market learns the new design rules and think out of the box, we will see that medical devices are more suited for 3D printing,” noted Chafino, additive manufacturing expert at orthopedic instrument and implant developer/manufacturer InTech, Chatellerault, France. “The future of 3D printing is linked to the advances on software technologies in terms of applications and technology itself. An orthopedic digital twin of a human body will unlock the full potential of patient-specific implants for simulation purposes to ensure the kinematics are optional, which will improve patient outcomes while extending the lifespan of the medical device itself.”
This is their more medical oriented 3D printing collab.
The collaboration is focused on the biomedical and investment casting industries.
“We are excited about the possibilities of creating a silicon nitride-based resin for the biomedical market. With interest in silicon nitride medical devices continuing to grow rapidly, we believe 3D printed silicon nitride devices will play a major role in the future of medical and technical segments in which we participate
2017 article on 3d printed bone...
Working with two engineering students in Welfare Technology, Professor Morten Østergaard Andersen has developed the artificial bone material which the 3D printer uses to build the bones. The results from the mouse experiments show that the mouse’s own skull accepts the artificial bone and then eats into the artificial bone, which disappears in time. To help the process along, the researchers graft stem cells onto the bone.
Ceramic bone-like materials, generally hydroxyapatite (HAP or HA) for durability or tricalcium phosphate (TCP) for osteointegration can be 3D printed using stereolithographic 3D printing processes such as those proposed by Lithoz, 3DCeram and Prodways or through precision deposition (micro-dispensing) using systems such as the EnvisionTEC 3D bioplotter or nScrypt’s micro-dispensers.
In February of 2024, the company announced a multiple year supply agreement with a leading aerospace company.
What if a hip or knee replacement could be printed in 3-D???
You can take Zimmer Biomet M&A with Sintx out of the picture but you cant take the fact that its a strategic partner with Sintx in regards to Hip/Knee. Because Zimmer Biomet was working with Sintx on a hip implant pertaining to the use of Sintx femoral head and the fact that Sonny was pals with former ZB CEO Dvorak, you can bet Hanson is aware of Si3N4/Si3n4 imbued fabrics and thus Solventum is. A partnership to develop any products with Solventum/3M to utilize Si3N4 imbued fabrics explains why things happened the way they did with O2...at least on the R&D front. It also explains why theres been no new developments in regards to commercializing masks as Solventum only completed its spin-off from Q1 this year.
Morgan Ceramics was a partner with Sintx in 2016 and theres no reason to believe it still isnt in regards to Aerospace products as
Since NP Aerospace was part of Morgan Ceramics at the time of Morgan Ceramics partnership with Sintx, the fact that NP Aerospace uses the very materials that Sintx Armor supplies, that Bray comes from NP Aerospace, and the fact that NP Aerospace needs a US manufacturing location, its not a leap in logic to see that Sintx was setup to supply NP Aerospace in the armor department. Thus it explains what Sintx is waiting on in regards to NP Aerospace.
Partnerships help explain some of the execution as well so no M&A with Zimmer Biomet is not required. To me it just makes the most sense for Zimmer Biomet to acquire Sintx in the end because of how Sonny is setting Sintx up to give any entity that acquires it for licensing revenue and that was Zimmers intentions 13 years ago. Now i havent seen any action that goes against this original plan. As shown with Eli and Amylin, things can change./quote]
See replied to post
I'm sure THAT will not happen....
Thanks for the additional info...
Defense & Aerospace would be even more lucrative ( unfortunately this is the priority today's world)
Prodways is promoting dental implants, so that is covered, that appears to be plastic, but the tech is proven for bio fitting.
I was thinking bone replacement, which would be additive to the dental franchise and open up a lot of new medical business.
Perhaps it is for multiple human biological applications:
The team’s 25 years of experience makes SINTX an attractive development partner for Prodways, a manufacturer of 3D printers and a leader in the additive manufacturing industry. SINTX has been actively 3D printing ceramics with the Prodways L5000 since 2018, SINTX is excited to benefit from the technical advancements from the latest Prodways hardware innovations as part of this partnership.
Prodways, a pioneer in industrial 3D printing, will be able to leverage SINTX’s Silica and Alumina qualified slurries on the latest MovingLight machine generation, specifically developed for the demanding requirement of ceramic application. In particular, the machine will provide a unique combination of high resolution and build envelope, while maintaining process scalability with flexible build envelope configuration and process-oriented parameters control.
Ann Kutsch, General Manager of the SINTX-Maryland site, commented: “Our outstanding engineering team has 6 years of experience working with Prodways printers, and we have already used their equipment to commercialize multiple resin compositions and part designs. I expect that a more formal partnership will lead to some breakthrough developments and novel solutions for all our customers.”
Vincent Icart, CTO and COO of Prodways, added “Prodways has had a very early exposure to ceramics 3D printing. Before this partnership, we were only supplying customers with internal capabilities development. We are thrilled to bolster our specifically developed MovingLight machineries with SINTX slurries, as our joint expertise will allow us to be an end-to-end solution provider for the most demanding ceramic printing applications.”
They also do Defense & Aerospace which today's PR pertains to. The slurries being provided are not their Silicon Nitride...at least not yet. Hopefully it leads to 3D printing dental implants but thatd be a different collab.
More interesting info...
boston745
Member Level
Re: None
Thursday, March 21, 2024 3:32:25 PM
Post# 40663 of 40935
Interesting pattern of increased attacks on me around the time of increased naked shorting of the stock; although this is not 100%. We will not know for a month, but yesterdays volume may have been accompanied by an increase in naked shorting as there was on the 21st of February. Attacks on me, i suspect are more than just to distract from what i post but also because they know that will prompt a typical response of posting information to defend Sintx real valuation. Which, they then utilize to help craft their narrative that Sintx is a scam and im paid or just crazy. However i post information regardless if the stock price drops or trades sideways here just like i post warning about Tesla on its forum regardless of which direction the stock goes. The best defense against such attacks is to read the research, which is heavily sourced, and watch the other posters in action. I include the claim that 911 was an inside job, along with the evidence that supports this claim, knowing to some this will make me look crazy, which only aids their crazy claim. However i do this purposefully.
I use evidence to point to Sintx eventual success. At the same time a counter element lead by hfunds drives the price lower via naked shorting, to aid in lowering of the VWAP strike price, and converting their warrants cashless (free shares). The funds benefit by driving the price lower to lower their VWAP and reverse split to lower it even further as seen since the 100:1 RS to end 2022. They make alot of money shorting this and get the tax write off on the original investment "loss".
Almost all posters on SINTX forums, with the exception of myself, are aligned with the goal of price going lower. In part this is so there is no collateral damage of people losing too much money on SINT; they warned me to sell early last year before they drove the price to where it is today with nothing bad actually happening with the company to support such a drop in price. However while collateral damage maybe a motive, it is not the only reason. Another reason is keeping people away from SINT by making it look like its a scam, allows them to manipulate the price unimpeded, while reducing the likelihood of investigations by the SEC and lawsuits. All the while they point the finger at Sonny and management or even me.
Fails-to-Deliver Data
https://www.sec.gov/data/foiadocsfailsdatahtm
DD relevant to today's announcement, see replied to post...
Excerpt:
SINTX Technologies Awarded Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants
SINTX will collaborate with the University of Pennsylvania School of Veterinary Medicine (Penn Vet) over the next 24 months to execute this project. The NIH grant will support resourcing and acquisition of materials as well as testing and trials at SINTX and Penn Vet. Upon the successful execution of the Phase II grant application goals, SINTX will have the majority of the benchtop and large animal in vivo data needed to seek FDA regulatory clearance using the 510(k) pathway. Additionally, successful demonstration of infection prevention in vivo will be a critical step towards enabling an antimicrobial device claim. These preliminary animal data will be used to seek future funding from NIH or other Federal agencies to further validate antimicrobial properties of devices made from SN-PEEK.
announced today it has been awarded a Phase II grant of $1,972,826 by the National Institutes of Health (NIH) to develop a 3D printed (3DP) composite silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This represents the fourth NIH grant awarded to SINTX since the Phase I award for this project was received in September of 2021.
Representing approximately 40% of spine implants within the $10 billion global spine market, PEEK-based devices are favored because of their proven clinical efficacy. Through the development of 3DP SN-PEEK spinal implants, SINTX aims to combine the familiarity and benefits of PEEK with the antibacterial and osteoconductive characteristics of silicon nitride. These composite implants will be manufactured with modern, cost-effective 3D printing technologies.
https://ir.sintx.com/news-events/press-releases/detail/216/sintx-technologies-awarded-phase-ii-nih-grant-for-silicon
Next news company buying back shares coming 🚀💲
The more I read the more I like...
Applications » Health » Medical
3D printing medical devices
The right printing solution. Perfect patient fit.
Every body is unique.
As medicine continues to strive for better care, technology is letting surgeons, technicians and prosthetists grasp this incredible truth: The best devices are the ones uniquely made to fit each individual patient.
Custom orthopedics, braces, implants and orthotics are all changing patient care, while customized tools and preview models are empowering surgeons and other doctors to do better work than ever. But keeping up requires a 3D printing solution that’s perfectly fitted to the needs and applications you provide. Here’s how Prodways helps you build yours.
Still impressed:
Prodways Group Patents – Key Insights and Stats
March 21, 2024
Prodways Group has a total of 21 patents globally, out of which 14 have been granted. Of these 21 patents, more than 61% patents are active. The United States of America is where Prodways Group has filed the maximum number of patents, followed by Germany and Europe. Parallelly, the United States of America seems to be the main focused R&D centre and also France is the origin country of Prodways Group.
Prodways Group was founded in 2013. The Prodways Group offers 3D printing services. The business provides printing equipment for the automotive, industrial design, engineering and construction, industrial design, jewelry, footwear, and footwear sectors. As of February 2023, the market cap of Prodways Group is $152 Million.
Do read about some of the most popular patents of Prodways Group which have been covered by us in this article and also you can find Prodways Group patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Prodways Group patent portfolio.
I'm impressed...
https://www.prodways.com/3d-printers/movinglight-dlp/
$SINT NICE 0.0579+0.0175 (+43.3168%)
IMO - they don't have a product yet, so they have nothing to announce.
Their dental product suggests that they have the know-how to follow through.
https://www.prodways.com/application/health/dental
Looked on Prodways website. Can't even find an announcement. They had revs of about 80 mil last year but ended up with a minus in the net dept. Still, it looks like a decent co. and of course I can't find any mention from this side as to what the potential numbers are with such a partnership. Usual fluff imo, but as always, we'll see. Hope to see different....
$SINT OVER 100M VOLUME ALREADY STOCK EXPLODING
0.0519 +0.0115 (+28.4653%)
$SINT Good News: SINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENT
https://finance.yahoo.com/news/sintx-prodways-agree-ceramic-slurry-131400972.html
Keep slapping! .10 here we come!
Dollar land coming
$SINT Exploding
0.0510 +0.0106 (+26.2376%)
Billions $$$$$$$ Fish on reeling $$$$$$
Perfect timing with that news
SINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENT
$SINT looking good on
Pre-market 0.041 +0.00030 (0.74%)
This is a money printing scam has been since ipo Pumps into rs then dilutes to Pennies.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
One thing particularly interesting since the 2022 RS was the fact that with each announcement of offering the price of the stock would immediately drop 50% or so. That's before such an offering was even closed. Before new shares hit market. Then, because of the exact mechanism I described in my last post the price would be naked shorted another 50% post offering. So if the price was at 50 cents on announcement of a forthcoming offering, offering price then occurred at .25, and then closed out at 12.5ish post offering. There it stood for awhile until the next halving at 4.7 cents.
No negative news was released by the company to justify these drops, it just dropped because it could. However it did this repeatedly showcasing a pattern which shows purpose and collusion. The one major anomaly was when the stock was trading in the 8-9 dollar range and the offering was announced, for some reason at 5.6. Look at the trading history. The stock price hit a high of $12.14 in the 3 trading days before the offering price was announced at 5.6. Then the next day the price halved the previous days low to the low 3's. Funds naked shorted into that offering from as high as 12.14. SEC needs to investigate the trading that has occurred in regards to SINT and the short & distorting thats gone on via social media.
To keep interested buyers away, funds point to how poorly the stock has traded while ensuring it trades that way to support these types of posts, cyclical in nature. Outside of that shorts mostly have to employ deceptive pratices in their posts. These deceptive practices would not be necessary if the company was as bad as they would have people believe.
Take for example this post on ST.
This is a money printing scam has been since ipo Pumps into rs then dilutes to Pennies.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
I think my next round of research will be oriented toward showing that hedge funds prefer companies in SIntx position which provide them with near risk free profits and quick liquidity. Meaning these Hfunds want to keep SINT undervalued. Low prices allow for greater returns as % movements are larger with less capital needed. They would also be after control of the stock and to scare investors away to maintain that control. This could be another reason hfunds preform better when companies stocks are in bearish conditions. We all know Hfunds are the ones that engage in P&D activities and they like to use companies management as a scapegoat for their actions.
As shown with the offering round at .25, hedge funds naked shorted from as high as .52 cents before even buying a share. They made millions (paper returns) before even buying the offering and then closed out those naked shorts at .15 or so in the span of like 2-4 days. If they are still around then they successfully shorted from there profiting further. This cycle is why SINT is so undervalued. Hedge funds do not care if long or short but they seem to be more profitable in a bear market (holding short) than bull (holding long) because they can better play the up and down. SINT has been in a bear market conditions since IPO. Its these same hedge funds pumping the price now to increase their profits especially as they'll be shorting the RS because they will get guaranteed profits shorting into the next offering.
Hedge Funds Actively Seek Absolute Returns
Hedge funds lie at the active end of the investing spectrum as they seek positive absolute returns, regardless of the performance of an index or sector benchmark. Unlike mutual funds, which are "long-only" (make only buy-sell decisions), a hedge fund engages in more aggressive strategies and positions, such as short selling, trading in derivative instruments like options, and using leverage (borrowing) to enhance the risk/reward profile of their bets.
This activeness of hedge funds explains their popularity in bear markets. In a bull market, hedge funds may not perform as well as mutual funds, but in a bear market—taken as a group or asset class—they should do better than mutual funds because they hold short positions and hedges.
In hedge funds, liquidity is a key concern for investors.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
This is what a scam looks like TA since you arent able to differentiate. Although i do believe there is a con going on here and that con is to convince people that Sintx's IP value isnt significantly more than it is. That management is more inept than it is. That Sintx isnt working with companies evidence clearly show its working with. This is why accounts like yours TA have to continually resort to deceptive tactics in their posts. The stockprice is clearly being manipulated to help drive these narratives and force those RS you like to point to. IF the stock price properly reflected Sintx IP value, in the hundreds of millions, Sintx wouldnt need to do as many offerings because it could raise more per offering, it wouldnt "print" as many shares, and wouldnt have needed to RS. Heads Will Roll it was arguably a referendum on “fake it till you make it” practices, such as intentionally overstating, and thereby misrepresenting, a fledgling company’s current capabilities, success, or profitability, while banking on the notion that its aspirations will eventually follow the desired trajectory and become a reality.
My stance on Tesla is its a bigger 'Fake it Until it Makes it Scam' than that of Theranos! A scam thats putting so many lives at risk!
Facebook Cofounder Says Tesla Has Committed "Consumer Fraud on a Massive Scale," Will End in Jail
Amidst a chaotic month for Tesla — even by its continuously plunging standards — Facebook cofounder and multi-billionaire Dustin Moskovitz has made some pretty dire predictions for the automaker, accusing it of committing "consumer fraud on a massive scale."
"This is Enron now, folks," Moskovitz wrote on Threads, referring to the corporation that went bankrupt in 2001 after it was exposed for one of the biggest accounting frauds in history. "It may keep going, but people are going to jail at the end."
No idea about whether Tesla is engaged in book cooking, this is not the first time its been accused of that, but consumer fraud on a mass scale definitely seems accurate. Just look at what falls under fake it until you make it practice and then compare to actual actions taken by Elon Musk and Tesla.
Elon Musk slashes price for Tesla’s vaunted self-driving tech by a full third—FSD now costs as much as in 2020
Rolled out to a select few three and a half years ago, the highly anticipated beta gave Musk the opportunity to hike the cost of FSD to $10,000. He would continue to urge his loyal customers to buy FSD, since the longer they waited, the more it would cost them.
That’s because Musk repeatedly claimed the price would go up the better the software got and the closer FSD came to driving without human supervision, at which point, he boasted, it would be worth over $100,000. Initially he also kept his word: Two subsequent hikes, which culminated in a record increase to $15,000 in 2022, were pushed through despite no substantive progress having been made.
The issue was that take rates had plummeted after customers broadly gave up on his annual promise of a breakthrough next year. He had to resort last month to compulsory trials when new owners picked up their car for the first time. Attempts to license the technology to rival carmakers also collapsed, he admitted in January.
In a way, Musk has given up on FSD as well. In what appears to be an acknowledgement that existing owners will not experience their cars turning into robo-taxis overnight—what Musk called Tesla’s “ChatGPT moment”—he opted to simply end the beta test in favor of calling the software “supervised FSD.” This opens up the chance to recognize nearly $926 million in deferred revenue
Not long before the pandemic reared its ugly head, the brilliant, serial entrepreneur Elon Musk promised to roll out an Uber-like service enabled by self-driving Tesla vehicles. According to Musk, Tesla owners could expect to earn up to $30,000 per year in extra cash by lending their Teslas out to anyone in need of a ride. Owners and customers would transact on the “Tesla network.”
This self-driving technology already exists. At this point, the network can go live very soon, opening the world to an exciting new way to make money while you sleep.
Back in 2016, Elon Musk claimed that Tesla cars could “drive autonomously with greater safety than a person. Right now.” It was a lie, one that sent Tesla’s stock price soaring — and made Musk among the wealthiest people on the planet. That lie is now falling apart in the face of a new recall of 2 million Teslas. It’s also revealing to the broader public what close observers of Tesla have always known (and the company itself admits in the fine print of its legal agreements): Tesla’s so-called “self driving” technology works fine — as long as there’s a human behind the wheel, alert at all times.
By this time Musk had MCed numerous stock price-spiking hype events around the technology, and had been collecting deposits from customers since late 2016 for a “Full Self-Driving” version of the technology. Despite the reported deaths and clear evidence that the only video of a driverless Tesla was heavily staged, even Musk admits that his hype around self-driving technology has been the central factor in the recent growth of his wealth to titanic proportions.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
I said you can take buyout out of the equation but that doesn't change whats being done with strategic partners.
Let's try this again.
Zimmer Biomet partner innregards to Hip/knee
Thus Solventum could be a partner in regards to Si3N4 imbued fabrics. Commercialization with Solventum on any of the Si3N4 imbued fabrics explains to some degree why things happened the way they did with O2. You were one of those name dropping 3M back in 2020 if you remember.
Morgan Ceramics was Sintx aerospace partner back in 2016 and now Sintx is supplying a leading global aerospace supplier. Are we to believe that Morgan did that R&D work just to watch Sintx supply a different company?
During that time NP Aerospace was part of Morgan Ceramics. This armor division of Morgan is now its own company. Bray left Morgan Ceramics when NP Aerospace was spun off and lands at Sintx 6 months later where he begins setting up Sintx armor division and supply the very ceramic materials NP uses per one of their parents. This suggests that Sintx is setup to supply NP Aerospace.
On dental front, as Sintx was partnered with Zimmer Biomet in regards to femoral head, Sintx could easily have a partnership with Zimvie if Zimvie stays a dental company. Dentsply was another dental partner who wouod use Sintx Si3N4 assuming dental products move forward. This is because Sintx is setup as an OEM supplier as Zimmer intended back in 2011.
None of that requires an acquisition. Sintx is setup to me acquired though. Its not really setup to grow as a standalone entity. Meaning I dont see it ever becoming the Invibio of ceramics. In theory it could.
See you are incapable of separating a buyout from an investment thesis to evaluate management’s execution. And you wonder why you can’t comprehend why this stock/company is where it is.
Keep howling in the wind about conspiracies, doing wonders for you.
You can take Zimmer Biomet M&A with Sintx out of the picture but you cant take the fact that its a strategic partner with Sintx in regards to Hip/Knee. Because Zimmer Biomet was working with Sintx on a hip implant pertaining to the use of Sintx femoral head and the fact that Sonny was pals with former ZB CEO Dvorak, you can bet Hanson is aware of Si3N4/Si3n4 imbued fabrics and thus Solventum is. A partnership to develop any products with Solventum/3M to utilize Si3N4 imbued fabrics explains why things happened the way they did with O2...at least on the R&D front. It also explains why theres been no new developments in regards to commercializing masks as Solventum only completed its spin-off from Q1 this year.
Morgan Ceramics was a partner with Sintx in 2016 and theres no reason to believe it still isnt in regards to Aerospace products as
Since NP Aerospace was part of Morgan Ceramics at the time of Morgan Ceramics partnership with Sintx, the fact that NP Aerospace uses the very materials that Sintx Armor supplies, that Bray comes from NP Aerospace, and the fact that NP Aerospace needs a US manufacturing location, its not a leap in logic to see that Sintx was setup to supply NP Aerospace in the armor department. Thus it explains what Sintx is waiting on in regards to NP Aerospace.
Partnerships help explain some of the execution as well so no M&A with Zimmer Biomet is not required. To me it just makes the most sense for Zimmer Biomet to acquire Sintx in the end because of how Sonny is setting Sintx up to give any entity that acquires it for licensing revenue and that was Zimmers intentions 13 years ago. Now i havent seen any action that goes against this original plan. As shown with Eli and Amylin, things can change.
Remove the buyout from the thesis and the 8 other companies you try to tie it to.
The company is horribly mismanaged and execution has been nothing short of dogsht.
Looks like TA, that madg posted that so you could then post that im posting BS when i replied. I realize that me posting this could add to the illusion that Sintx is a scam. Yet i persist.
Its funny that Sintx selling its spinal IP and Amedica name to CTL is actually action aligned with Zimmer Biomets goal to license Sintx core tech outside of Hip/Knee as stated back in 2011.
If masks, and/or any other Si3n4 imbued fabric product, end up being commercialized with Solventum at any point, which would be ironic considering bashers were the first to name drop 3M before Hanson even left Zimmer Biomet for its spin-off Solventum, then everything that happened with O2 makes sense. So much of what happens with Sintx makes sense if you understand that Sonny is aligning Sintx with Zimmer Biomet strategic goals.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
If Sonny is aligning Sintx with Zimmer Biomets core goals as I think then Sintx isnt being mismanaged but its actions simply misunderstood. That misunderstanding is being exploited by those shorting SINT and trying to convey mismanagement. Again the core Ip is very valuable and has expanded immensely. Yet that value is not reflected at all in the stockprice or marketcap.
But its so much more than simply an acquisition madg and you should know that by now! I post this with almost every post. Pay particular attention to section 3 & 1. 2 is just reinforment that Si3N4 is next gen Hip/Knee material confirming exactly why Zimmer Biomet would want the tech for its most important product lines.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
$SINT huge a ask slapping again How high will it go to the Moon maybe?
0.0416+0.0050 (+13.6612%)
Spiking! .05 close???
Followers
|
240
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
41284
|
Created
|
02/13/14
|
Type
|
Free
|
Moderators Atlanta1 Tesla thru the roof |
https://www.youtube.com/watch?v=j94SgeyCh3M
(AMDA) Amedica Corp. - NASDAQ
RECENT NEWS
https://www.youtube.com/watch?v=hxbj7Sq7W94
https://www.youtube.com/watch?v=j94SgeyCh3M
https://www.youtube.com/watch?v=KbU47COpXx8
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |